FDA Approval for CYLOX® ST

Alzenau, 26/02/2025 – SIGNUS Medizintechnik GmbH is proud to announce the successful FDA approval of the CYLOX^® ST cage and plate system. This FDA clearance marks a significant milestone in the expansion of our product range in the US market as well as in advancing spinal care, ensuring improved patient outcomes and procedural efficiency.

SIGNUS is dedicated to the continuous development of innovative products with passion and precision, providing customers the most advanced solutions.

The ST-line by SIGNUS is focusing on improved osseointegration in spinal surgery. Intervertebral fusion implants made of structured titanium (ST) create all of the conditions which are essential for successful osseointegration.

Additive manufactured spinal implants offer an open, macroporous titanium design resembling natural cancellous bone architecture, promoting both bone-on growth and bone-in growth. This is crucial for long-term implant stability.

Therefore SIGNUS is constantly working on this enabling technology, applying it across a broad portfolio of spinal implants.

CYLOX® ST was developed for anterior cervical discectomy fusion (ACDF) (C3 – TH1). This innovative device offers surgeons a wide variety of options: to implant the cage with integrated screws, as a cage and plate combination or even in combination with one of our cervical plates, ASCOT® or TOSCA®. The CYLOX^® ST cages are available in various designs, footprints, heights, and angles to enable adaptation to different patient anatomies.